BridgeBio Pharma Launches Eidos Therapeutics to Develop Targeted Therapy for Fatal Heart Disease

PALO ALTO, Calif., April 27, 2017 /PRNewswire/ — BridgeBio Pharma today announced the launch of Eidos Therapeutics, a biopharmaceutical company developing a novel small-molecule treatment for transthyretin (TTR) amyloidosis. BridgeBio has committed $27 million and seasoned R&D executives to advance Eidos’ lead compound, AG10. “TTR amyloidosis is a progressive, fatal disease without an FDA-approved therapy. Patients and their families currently rely on […]